Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Effect of LY2189265 on Blood Pressure and Heart Rate in Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Type 2 diabetes taking 1 or more oral diabetes medications and have taken these medications for at least 1 month prior to screening~* Glycosylated hemoglobin (HbA1c) value ≥7% and ≤9.5% at screening~* Mean blood pressure \>90/60 millimeters of mercury (mmHg) and \<140/90 mmHg at screening~* If treated for hypertension, are taking 3 or less antihypertensive medications and have been taking these medications for at least 1 month prior to screening~* Stable weight for 3 months prior to screening~* Body mass index (BMI) greater than or equal to 23 kilogram-meter squared (kg/m\^2)~* Willing to wear an ambulatory blood pressure monitoring device for at least 24 hours on multiple occasions~* Women of childbearing potential must test negative for pregnancy and be willing to use a reliable method of birth control~* Male participants must use a reliable method of birth control~Exclusion Criteria:~* Myocardial infarction, stroke, or hospitalization for heart failure within 3 months prior to screening, or heart failure Class III or IV at screening~* Ongoing or history of frequent intermittent tachyarrhythmia~* Resting heart rate \<60 beats per minute (bpm) or \>100 bpm at screening~* Work rotating shifts or work during the hours of 2200 to 0700~* Chronic insulin therapy~* Use of a glucagon-like peptide 1 (GLP-1) receptor agonist within 3 months prior to screening, or a dipeptidylpeptidase-IV (DPP-IV) inhibitor within 2 weeks prior to screening~* Nondominant arm circumference \>42 centimeter (cm)~* Use of drugs to promote weight loss~* Chronic use of systemic steroids~* Gastric emptying abnormality or bariatric surgery~* Hepatitis, other liver disease, or alanine transaminase (ALT) \>3 times the upper limit of normal~* Acute or chronic pancreatitis~* Severe renal impairment~* Active autoimmune disease or uncontrolled endocrine abnormality~* Self or family history of thyroid cancer, medullary C-cell hyperplasia, or type 2A or 2B multiple endocrine neoplasia~* Calcitonin value greater than or equal to 20 picograms per milliliter (pg/ml) at screening~* Transplanted organ except corneal transplants~* Active or untreated cancer or in remission \<5 years, except skin, in situ cervical, or prostate cancer~* Sickle-cell disease, hemolytic anemia, or another hematological condition that may interfere with HbA1c testing

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1.5 milligram (mg) LY2189265 (Type: EXPERIMENTAL): LY2189265: 1.5 milligram (mg), subcutaneous (SC), once weekly (QW)
- 0.75 milligram (mg) LY2189265 (Type: EXPERIMENTAL): LY2189265: 0.75 milligram (mg), subcutaneous (SC), once weekly (QW)
- Placebo (Type: PLACEBO_COMPARATOR): Placebo: subcutaneous (SC), once weekly (QW)

Based on this trial design, predict the completion outcome and termination type (if applicable).